KIT and melanoma: Second, the genetic location of KIT mutation has successfully been used to guide selection of the KIT inhibitor in melanoma, echoing the broader experience of the use of KIT mutation subtype to select kinase inhibitor therapies in GIST (Heinrich et al, 2008).